Therapy-associated solid tumors

Acta Oncologica

Volumn 41, Issue 4, 2002, Pages 323-333

  Travis, Lois B ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOTHERAPY; DIAGNOSIS; PATIENT TREATMENT; TUMORS;

QUANTIFICATION;

ONCOLOGY;

ALKYLATING AGENT; AMIFOSTINE; ANTINEOPLASTIC AGENT; CHLORAMBUCIL; CHLORMETHINE; CYTOTOXIC AGENT; DNA; MONOCLONAL ANTIBODY; PREDNISONE; PROCARBAZINE; RADIOPROTECTIVE AGENT; VINCRISTINE;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RISK; CARCINOGENESIS; DIGESTIVE SYSTEM CANCER; ENVIRONMENTAL FACTOR; HODGKIN DISEASE; HOST; HUMAN; LEUKEMIA; LUNG CANCER; PRIORITY JOURNAL; RADIATION DOSE; REVIEW; SECOND CANCER; SMOKING; SOLID TUMOR; TESTIS CANCER;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; HUMANS; NEOPLASMS; NEOPLASMS, RADIATION-INDUCED; NEOPLASMS, SECOND PRIMARY; RADIOTHERAPY; RISK FACTORS;

EID: 0036352080     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/028418602760169361     Document Type: Review

References (114)

1. Late effects of cancer therapy
2. Second cancers
3. Multiple myeloma and acute myelomonocytic leukemia
4. Hodgkin's disease: Complications of therapy and excess mortality
5. Multiple primary cancers
6. Second cancers following radiotherapy
7. Second cancers in survivors of childhood cancer
8. Cancer incidence in atomic bomb survivors. Part II: Solid tumors, 1958-1987
9. Ionizing radiation
10. Thyroid cancer after exposure to external radiation: A pooled analysis of seven studies
11. Risk of second cancers after treatment for Hodgkin's disease
12. Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: The relation to age at treatment
13. Second cancers after treatment of Hodgkin's disease
14. Breast cancer after treatment of Hodgkin's disease
15. Breast cancer and other second neoplasms after childhood Hodgkin's disease
16. Risk of subsequent malignant neoplasms among 1641 Hodgkin's disease patients diagnosed in childhood and adolescence: A population-based cohort study in the five Nordic countries
17. Breast cancer after Hodgkin's disease
18. Radiation and breast carcinogenesis
19. Lung cancer after Hodgkin's disease
20. Lung cancer following Hodgkin's disease: A case-control study
21. Roles of radiotherapy and smoking in lung cancer following Hodgkin's disease
22. Lung cancer after Hodgkin's disease: A nested case control study of the relation to treatment
23. Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease
24. Gastrointestinal cancer after treatment of Hodgkin's disease
25. Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood
26. Second malignant neoplasms among long-term survivors of Hodgkin's disease: A population-based evaluation of 32591 patients over 25 years
27. Second malignancies following testicular cancer, ovarian cancer and Hodgkin's disease: An international collaborative study among cancer registries
28. Second cancer after the treatment for Hodgkin's disease: A report from the international database on Hodgkin's disease
29. Second cancers following pediatric Hodgkin's disease
30. Second cancers in long-term survivors of Hodgkin's disease diagnosed in childhood and adolescence
31. Risk of second malignant neoplasms among long-term survivors of testicular cancer
32. Incidence of second primary cancer following testicular cancer
33. Treatment of testicular cancer and the development of secondary malignancies
34. Second malignant neoplasms among long-term survivors of ovarian cancer
35. Radiation therapy for breast cancer and increased risk for esophageal carcinoma
36. Second cancer following cancer of the male genital system in Connecticut, 1935-82
37. Studies of the mortality of atomic bomb survivors. Report 12, Part I. Cancer: 1950-1990
38. Cancer incidence after retinoblastoma. Radiation dose and sarcoma risk
39. Radiation and genetic factors in the risk of second malignant neoplasms after a first cancer in childhood
40. Radiotherapy, alkylating agents, and risk of bone cancer after childhood cancer
41. A cancer family syndrome in twenty-four kindreds
42. The genetic defect in ataxia-telangiectasia
43. P53 and ATM: Cell cycle, death and cancer
44. Germ-line transmission of a mutated p53 gene in a cancer prone family with Li-Fraumeni syndrome
45. Cancer in patients with ataxia-telangiectasia and in their relatives in the Nordic countries
46. Heterozygous germline ATM mutations do not contribute to radiation-associated malignancies after Hodgkin's disease
47. Increased risk of breast cancer following irradiation for Hodgkin's disease is not a result of ATM germline mutations
48. Prevalence of germline truncating mutations in ATM in women with a second breast cancer after radiation therapy for a contralateral tumor
49. Markers of DNA repair and susceptibility to cancer in humans: An epidemiologic review
50. Nonconservative amino acid substitution variants exist at polymorphic frequency in DNA repair genes in healthy humans
51. Genomic instability induced by ionizing radiation
52. Radiation-induced genomic instability: Delayed mutagenic and cytogenetic effects of x rays and alpha particles
53. Cell-cell contact during gamma irradiation is not required to induce a bystander effect in normal human keratinocytes: Evidence for release during irradiation of a signal controlling survival into the medium
54. Unexpected sensitivity to the induction of mutations by very low doses of alpha-particle radiation: Evidence for a bystander effect
55. High-resolution haplotype structure in the human genome
56. Blocks of limited haplotype diversity revealed by high-resolution scanning of human chromosome 21
57. Fluorescent cDNA microarray hybridization reveals complexity and heterogeneity of cellular genotoxic stress responses
58. Molecular characteristics of non-small cell lung cancer
59. Clinical proteomics. Personalized molecular medicine
60. Molecular profiling of human cancer
61. Profiling of cancer cells using protein microarrays: Discovery of novel radiation-regulated proteins
62. Genetic epidemiology
63. Conformal radiotherapy and intensity-modulated radiotherapy - Clinical data
64. Risk analysis of linear accelerator radiosurgery
65. Principles of radioimmunotherapy for hematologists and oncologists
66. Complications from arteriovenous malformation radiosurgery: Multivariate analysis and risk modeling
67. Tumors of the brain and nervous system after radiotherapy in childhood
68. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas
69. Correlation of marrow dose estimates based on serial pretreatment radiopharmaceutical imaging and blood data with actual marrow toxicity in anti-CD20 yttrium-90 monoclonal antibody radioimmunotherapy of non-Hodgkin's B-cell lymphoma
70. Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia
71. Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma
72. Bone sarcomas linked to radiotherapy and chemotherapy in children
73. Bone sarcomas as second malignant neoplasms following childhood cancer
74. Reactive chemicals and cancer
75. Antitumor alkylating agents
76. 6 position of guanine in DNA is the most likely initiating event in carcinogenesis by methylating agents
77. 6-methylguanine in human blood leukocyte DNA during exposure to procarbazine and its relationships with dose and repair
78. Tobacco smoke carcinogens and lung cancer
79. 6-methylguanine repair in fibroblast cultures from patients with lung cancer
80. Immunomodulatory effects of cigarette smoke
81. Drug interactions with tobacco smoking. An update
82. 6-alkylguanine DNA alkyltransferase gene in lung cancer risk
83. Predicting lung cancer by detecting aberrant promoter methylation in sputum
84. Second primary cancers related to smoking and treatment of small-cell lung cancer
85. Second cancers following chronic lymphocytic leukemia
86. Second cancers among long-term survivors of non-Hodgkin's lymphoma
87. Role of N-nitroso compounds (NOC) and N-nitrosation in etiology of gastric, esophageal, nasopharyngeal and bladder cancer and contribution to cancer of known exposures to NOC
88. Chemotherapy-related second cancers
89. Risk of leukemia following platinum-based chemotherapy for ovarian cancer
90. Acute myeloblastic leukemia as a second malignancy in a patient with hereditary retinoblastoma
91. Carcinoma of the urinary bladder after treatment with cyclophosphamide for non-Hodgkin's lymphoma
92. Keystone address: Platinum-radiation interactions
93. Concomitant chemoradiotherapy: Rationale and clinical experience in patients with solid tumors
94. Second malignant neoplasms following treatment for Wilm's tumor: A report from the National Wilms' Tumor Study Group
95. High incidence of secondary brain tumours after radiotherapy and antimetabolites
96. Second malignant neoplasms in children: An update from the Late Effects Study Group
97. Treatment-associated leukemia following testicular cancer
98. Platinum-DNA adducts in leukocyte DNA of a cohort of 49 patients with 24 different types of malignancies
99. Persistence of platinum-ammine-DNA adducts in gonads and kidneys of rats and multiple tissues from cancer patients
100. Phase I and pharmacokinetic study of an oral platinum complex given daily for 5 days in patients with cancer
101. Oral platinum analogue JM216, a radiosensitizer in oxic murine cells
102. Biochemical pharmacology of chemotherapeutic drugs used as radiation enhancers
103. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix
104. Simultaneous radiochemotherapy in cervical cancer: Recommendations for chemotherapy
105. Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias
106. Radioprotectants: Pharmacology and clinical applications of amifostine
107. Amifostine pretreatment for protection against cyclophosphamide-induced and cis-platin-induced toxicities: Results of a randomized control trial in patients with advanced ovarian cancer
108. Has the outlook improved for amifostine as a clinical radioprotector?
109. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer
110. Programs for adult survivors of childhood cancer